VEGF overexpression in the proliferative phases of infantile hemangiomas is widely accepted, but the existence of biomarkers for assessing the therapeutic efficiency and for predicting post-therapy recurrence has not been outlined thus far. Here, VEGFA is linked to capillary hemangioma.